| Editorial | Financials |
Executive Committee
From left to right: Stephen G. Juelsgaard; David A. Ebersman; Ian T. Clark; Arthur D. Levinson; Richard H. Scheller; Susan D. Desmond-Hellmann; Patrick Y. Yang
|
Arthur D. Levinson, Ph.D. Dr. Levinson became chief executive officer of Genentech and joined the board of directors in July 1995. He was named chairman of the board in 1999. Levinson joined the company in 1980 as a senior scientist and subsequently held the position of staff scientist. He was named senior vice president, Research and Development in 1993 and president in 1995. He has been a member of Genentech's executive management team since 1990. Prior to his employment with Genentech, Levinson was a postdoctoral fellow in the department of microbiology at the University of California, San Francisco. Susan D. Desmond-Hellmann, M.D., M.P.H. Dr. Hellmann was named president, Product Development in 2004. She joined Genentech in 1995 as a clinical scientist and was named executive vice president, Development and Product Operations in 1999. Prior to joining Genentech, Hellmann was associate director of clinical cancer research at Bristol-Myers Squibb's Pharmaceutical Research Institute. Trained as an oncologist, Hellmann spent several years treating patients in the clinical setting. Ian T. Clark Mr. Clark joined Genentech's executive committee in August 2005 as senior vice president, Commercial and was promoted to executive vice president, Commercial in December 2005. Clark first came to Genentech in January 2003 as senior vice president and general manager, BioOncology. Prior to joining Genentech, Clark served as president of Novartis Canada. Before assuming his post in Canada, Clark served as chief operating officer for Novartis United Kingdom. David A. Ebersman Mr. Ebersman assumed the chief financial officer position in March 2005. He was promoted to executive vice president in December 2005. Ebersman joined Genentech in 1994 as a business development analyst. During the next several years, he was promoted to positions of increasing responsibility in Business Development, Product Development and Product Operations. Ebersman served as senior vice president, Product Operations and most recently, as senior vice president, Finance. |
|
Stephen G. Juelsgaard, D.V.M., J.D. Mr. Juelsgaard was promoted to executive vice president in September 2002 and named chief compliance officer in 2005. He joined Genentech in 1985 as corporate counsel. In 1993 he became vice president, Corporate Law, and in 1994 he was named vice president and general counsel. He was named secretary in 1997 and senior vice president in 1998. Richard H. Scheller, Ph.D. Dr. Scheller was promoted to executive vice president, Research in September 2003 after joining Genentech in 2001 as senior vice president, Research. In addition to his work at Genentech, Scheller is an adjunct professor in the Department of Biochemistry and Biophysics, School of Medicine, University of California, San Francisco. He is a member of the National Academy of Sciences and has published more than 200 papers in peer-reviewed scientific journals. Prior to joining Genentech, Scheller served as professor of Molecular and Cellular Physiology and of Biological Sciences at the Stanford University Medical Center and as an investigator with the Howard Hughes Medical Institute. Patrick Y. Yang, Ph.D. Dr. Yang was promoted to executive vice president in December 2005. He joined Genentech in 2003 as vice president, South San Francisco Manufacturing and Engineering and was named senior vice president, Product Operations in January 2005. He became a member of the Executive Committee in July 2005. Prior to joining Genentech, Yang spent 11 years at Merck & Company in various leadership positions, including vice president, Supply Chain Management and vice president, Asia/Pacific Manufacturing Operations. Prior to Merck, Yang worked for General Electric for 12 years in engineering and manufacturing. |